top of page

About Us

Image by Mufid Majnun

About Minute Molecular

Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $31.5 million in funding from the NIH and Diagnostic Industry Executives.  

Minute Molecular developed an innovative point-of-care PCR testing system that is able to provide central lab precision in as little as 10 minutes. Other unique features of the platform include the ability to use various sample types (nasal swab, saliva, whole blood, etc.) and quantitatively report a viral load.

Minute Molecular recently merged with Nuclein to advance its ultrafast, low-cost, point-of-care DASH™ PCR Platform. The Nuclein management team will be responsible for daily operations moving forward. Minute Molecular’s former leadership team (listed below) will continue to support the company in a variety of ways, including Minute Molecular’s former Chief Operating Officer, Wally Narajowski, joining Nuclein’s Board.

Former Leadership Team

David Kelso

Fmr. President and CEO

Sally McFall

Fmr. Chief Scientific Officer

Walter Narajowski

Fmr. Chief Operating Officer

Kara Palamountain

Fmr. VP Marketing

marc pic.jpg
Marc Minkus

Fmr. VP Operations

Former Board of Directors

Jack Schuler

Jack Schuler served on the Board of Directors of Minute Molecular Diagnostics, Inc.  He also has served as a Director of Biodesix since June 2008. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the board from 1995 until Ventana’s acquisition by Roche in 2008. Prior to joining Ventana, Mr. Schuler was President and Chief Operating Officer of Abbott Laboratories, a diversified health care company, which he joined in 1972 and where he held a number of management and marketing positions, also serving as a director from April 1985 to August 1989. Additionally, Mr. Schuler has served as a director of Abbott Laboratories (NYSE:ABT), Medtronic (Lead Director) (NYSE: MDT), Stericyle (Chairman) (NASDAQ: SRCL), Chiron Corporation, and Quidel Corporation  (NASDAQ: QDEL), and currently serves on the board of directors of Accelerate Diagnostics (NASDAQ: AXDX). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University Graduate School of Business Administration.

David Milligan

David V. Milligan, Ph.D. served on the Board of Directors of Minute Molecular Diagnostics, Inc. Dr. Milligan is a graduate of Princeton University and earned MS and PhD degrees in Chemistry from the University of Illinois.  Dave began his career with 3M Company and subsequently joined Abbott Laboratories where he held a number of R&D and business management positions.  He retired in 1996 as Senior Vice President and Chief Scientific Officer. Dave then joined Bay City Capital, a San Francisco life sciences investment firm, where he is now an advisor. He has served as a director of a substantial number of early stage companies including Reliant, Vicuron and Icos Pharmaceuticals as well as Caliper Diagnostics all of which achieved successful exits via acquisition by major companies.  In addition to being Chairman and co-founder of Xoult and Ekatra, Dave is currently a director of Inspirotec, an early stage private company, as well as Madrigal Pharmaceuticals which is public (MDGL).

Former Board of Advisors

Art D. Collins

Art Collins served on the Board of Advisors for Minute Molecular Diagnostics, Inc.  He is also a past director of Alcoa, Arconic, Boeing, Cargill, Tennant and US Bancorp. He has served as a member of the Board of Overseers of the Wharton School at the University of Pennsylvania and as chairman of AdvaMed, the medical technology industry association.

Art was chairman & CEO of Medtronic from 2001-2008, previously serving as the company's president & COO since 1994. He joined Medtronic in 1992 as president of Medtronic International. During his tenure as CEO and COO, revenues and earnings per share both grew at a compound growth rate in excess of 15%. Medtronic, the world's largest medical technology company, has been cited as one of the most admired companies, known for strong corporate governance and community involvement.

Art joined Medtronic from Abbott Laboratories where he had been corporate vice president responsible for Abbott's worldwide diagnostic business units since 1986. He began his career with Abbott in 1978 as manager of corporate planning. While at Abbott, he held a number of general management positions in the U. S. and Europe. Before joining Abbott, he served as a line officer in the U. S. Navy from 1969 to 1973. From 1974 to 1978, he was a consultant with Booz, Allen & Hamilton in Chicago.

Art served as a senior advisor at Oak Hill Capital Partners from 2008 to 2019. In addition, he and Sophia Shaw, retired CEO of the Chicago Botanic Garden, in 2016 formed Acorn Advisors, LLC, a consulting firm focused on governance and strategic planning for nonprofit organizations and large family offices. He also authored The Adventures of Archibald and Jockabeb, a 9-book series of children's adventure stories.

Art received a BS degree and an honorary Doctor of Laws degree from Miami University. He holds a MBA degree from the Wharton School of the University of Pennsylvania where he was a member of the undergraduate faculty and a recipient of the Joseph Wharton Lifetime Achievement Award. 

William (Bill) Rutter

William J. Rutter, Ph.D. served on the Board of Advisors for Minute Molecular Diagnostics, Inc. Dr. Rutter is also the Founder and Chairman and CEO of Synergenics, LLC, which controls a consortium of companies with different but complimentary approaches to diagnosis, prevention and treatment on a worldwide basis. Previously, Dr. Rutter was co-founder and chairman of Chiron Corporation, a major biotechnology company which is well known for the development of recombinant DNA-based vaccines, including Hepatitis B, and for the discovery of Hepatitis C, the first sequencing of the HIV-AIDS virus. Chiron pioneered the development of quantitative DNA-based diagnostic tests measuring viral load, which has played a major role in protecting the blood supply, and also in developing drugs for treatment of these diseases.  Chiron was acquired in two stages by Novartis and its antecedent company Ciga-Geigy.  Dr. Rutter has served on boards of Novartis and several Biotech companies, including Cytokinetics, Sangamo Biosciences, and Synergenics companies.  Dr. Rutter is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.  Dr. Rutter has published 381 scientific articles and holds 26 patents and patent applications.  Previously, Dr. Rutter served as Chairman of the Department of Biochemistry and Biophysics at UCSF.  His lab made key contributions to biotechnology and recombinant DNA technology, including cloning of the human insulin gene and the production in yeast of a virus-like particle for Hepatitis B, which was eventually used in the manufacture of a Hepatitis B vaccine.

bottom of page